<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pregestational (preexisting) diabetes mellitus: Obstetric issues and management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pregestational (preexisting) diabetes mellitus: Obstetric issues and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pregestational (preexisting) diabetes mellitus: Obstetric issues and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey L Ecker, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Camille E Powe, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erika F Werner, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The maternal and fetal prognosis in pregnancies affected by pregestational (also called preexisting) diabetes has improved dramatically over the past century with the availability of insulin and the implementation of intensive glycemic control. The key elements in management of these pregnancies are:</p><p class="bulletIndent1"><span class="glyph">●</span>Achieving and maintaining excellent glycemic control while avoiding hypoglycemia and diabetic ketoacidosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening, monitoring, and intervention for maternal medical complications and comorbidities (eg, retinopathy, nephropathy, hypertension, cardiovascular disease, thyroid disease), as well as obstetric complications (eg, nausea and vomiting of pregnancy, preeclampsia, preterm birth).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening and monitoring for fetal complications (eg, congenital anomalies, macrosomia, polyhydramnios, stillbirth) and anticipation of neonatal complications (eg, respiratory morbidity, birth trauma, neonatal hypoglycemia), with timely intervention to minimize adverse outcomes, when possible.</p><p></p><p>Most issues related to the obstetric management of pregnant patients with diabetes (type 1 or type 2) will be reviewed here. The obstetric management is largely based on clinical experience, data from observational studies, and expert opinion; there is limited evidence from randomized trials.</p><p>Four important additional issues are discussed in detail separately: preconception evaluation/counseling, antenatal glycemic management, intrapartum and postpartum glycemic management, and neonatal issues:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4441.html" rel="external">"Pregestational (preexisting) and gestational diabetes: Intrapartum and postpartum glucose management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/138420.html" rel="external">"Diabetic ketoacidosis in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)"</a>.)</p><p></p><p>Gestational diabetes is also discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6797.html" rel="external">"Gestational diabetes mellitus: Screening, diagnosis, and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4800.html" rel="external">"Gestational diabetes mellitus: Obstetric issues and management"</a>.)</p><p></p><p class="headingAnchor" id="H3734942617"><span class="h1">CLASSIFICATION OF DIABETES IN PREGNANCY</span><span class="headingEndMark"> — </span>The following classification system for diabetes in pregnancy is based on the mechanism of disease and correlates with pregnancy outcome [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Type 1 diabetes (autoimmune beta cell destruction, usually leading to absolute insulin deficiency):</p><p></p><p class="bulletIndent2">a. Without vascular complications</p><p></p><p class="bulletIndent2">b. With vascular complications (eg, nephropathy, retinopathy, hypertension, atherosclerotic cardiovascular disease, etc)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type 2 diabetes (progressive loss of insulin secretion, often in the setting of insulin resistance):</p><p></p><p class="bulletIndent2">a. Without vascular complications</p><p></p><p class="bulletIndent2">b. With vascular complications (eg, nephropathy, retinopathy, hypertension, atherosclerotic cardiovascular disease, etc)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gestational diabetes (diabetes diagnosed during pregnancy and not clearly overt [eg, type 1 or type 2 diabetes])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other diabetes (eg, genetic origin, drug- or chemical-induced)</p><p></p><p>This topic focuses on type 1 and type 2 diabetes; principles of management generally also apply to other forms of pregestational diabetes.</p><p>Traditionally, the severity of pregestational diabetes was categorized according to the White classification  (<a class="graphic graphic_table graphicRef79735" href="/z/d/graphic/79735.html" rel="external">table 1</a>) [<a href="#rid2">2</a>], which attempts to provide a standardized definition for describing pregnant individuals with diabetes and has some correlation with pregnancy outcome [<a href="#rid3">3,4</a>]. Because the White classes are not mutually exclusive, the presence/absence of vascular complications, as described above, is a better predictor of adverse outcome than the specific White class [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H2"><span class="h1">FIRST TRIMESTER</span><span class="headingEndMark"> — </span>Ideally, patients with pregestational diabetes have received preconception counseling to address maternal and fetal risks during pregnancy, worked with their providers to optimize glycemic control, and undergone preconception screening for common comorbidities (eg, retinopathy, nephropathy, neuropathy, hypertension, cardiovascular disease, thyroid dysfunction), with management of any issues that were identified. However, many pregnancies are unplanned and many patients do not receive preconception care; thus, a prenatal visit may be the clinician's first opportunity to assess the patient's baseline medical status and provide counseling.</p><p>Issues that should be covered in preconception and routine initial prenatal care counseling are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a> and  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment"</a>.)</p><p class="headingAnchor" id="H2343658012"><span class="h2">Maternal issues</span></p><p class="headingAnchor" id="H1358999857"><span class="h3">Glycemic management</span><span class="headingEndMark"> — </span>In the first trimester, the clinician should emphasize the importance of meticulous glucose self-monitoring and attention to glycemic control throughout pregnancy to reduce the risks of adverse pregnancy outcomes. Information on diet, insulin therapy, glucose monitoring, and glucose targets should be provided by clinicians with experience in management of diabetes during pregnancy. A team approach is often recommended to provide the necessary expertise. In addition to the obstetric providers, the team may include an endocrinologist, certified diabetes educator, nutritionist, and/or the patient's primary care provider.</p><p>Self-monitored glucose levels are obtained fasting and one or two hours after the first bite of each meal. In individuals taking insulin (which includes most patients with preexisting diabetes), glucose levels should also be obtained prior to administering insulin (eg, before meals, at bedtime). Target levels are:</p><p class="bulletIndent1"><span class="glyph">●</span>Fasting, preprandial, and nocturnal glucose 70 to 95 mg/dL (3.9 to 5.3 mmol/L) <strong>and</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One-hour postprandial glucose 110 to 140 mg/dL (6.1 to 7.8 mmol/L) <strong>or</strong></p><p class="bulletIndent2"><span class="glyph">•</span>Two-hour postprandial glucose 100 to 120 mg/dL (5.6 to 6.7 mmol/L)</p><p></p><p>For patients using continuous glucose monitoring, the target glucose range is 63 to 140 mg/dL (3.5 to 7.8 mmol/L), and the time in range goal is &gt;70 percent.</p><p>Patients with pregestational diabetes often have extra prenatal visits to review self-monitored glucose values, but virtual methods of communication can also be used for frequent exchange of information about glucose values and adjustments in insulin therapy [<a href="#rid7">7</a>]. Glycemic management during pregnancy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control"</a>.)</p><p>Insulin is the preferred therapy. <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> is an option for some patients. There are limited data for other commonly used noninsulin agents such as GLP-1 agonists, SGLT-2 inhibitors, and DPP-4 inhibitors, which should be avoided. An increased frequency of congenital malformation or other harmful effects on the human fetus has not been observed, but animal studies have reported increased occurrence of fetal damage. For example, in animals, SGLT-2 inhibitors have caused renal toxicity at developmental periods equivalent to the second and third trimesters in humans and GLP-1 agonists have caused vascular (heart, blood vessels) and skeletal (cranial bones, vertebra, ribs) abnormalities at maternal exposures below the maximum recommended human dose. (See  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management", section on 'Patients on preconception noninsulin antihyperglycemic agents'</a>.)</p><p class="headingAnchor" id="H1306818495"><span class="h4">Hypoglycemia</span><span class="headingEndMark"> — </span>The first trimester is a high-risk time for hypoglycemia [<a href="#rid8">8</a>], particularly for patients with type 1 diabetes. The contributing factors likely include increased efforts to obtain tight glycemic control, nausea and vomiting of pregnancy, and pregnancy-mediated increase in insulin sensitivity [<a href="#rid9">9,10</a>]. Patients experiencing significant hypoglycemia can benefit from loosened glycemic targets to restore hypoglycemia awareness and prevent serious hypoglycemia. Acute episodes of hypoglycemia are managed using standard approaches, with the exception that asymptomatic glucose levels in the upper 60s can be tolerated. (See  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management", section on 'Management of hypoglycemia'</a>.)</p><p class="headingAnchor" id="H1851756225"><span class="h3">Nausea and vomiting</span><span class="headingEndMark"> — </span>Nausea and vomiting, which is common and bothersome in early pregnancy, can make insulin management challenging. For example:</p><p class="bulletIndent1"><span class="glyph">●</span>Vomiting and/or less food intake than anticipated can lead to hypoglycemia and fear of hypoglycemia. Recurrent hypoglycemia and fear of hypoglycemia make it difficult to administer the necessary doses of insulin to control postprandial hyperglycemia. Treatment of hypoglycemia can also cause rebound hyperglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nausea and food aversions may lead to greater consumption of carbohydrates, which may lead to hyperglycemia.</p><p></p><p>For these reasons, we have a low threshold for initiating pharmacotherapy for nausea and vomiting in pregnant patients with diabetes. (See  <a class="medical medical_review" href="/z/d/html/6811.html" rel="external">"Nausea and vomiting of pregnancy: Treatment and outcome"</a>.)</p><p>Clinicians should also consider whether the nausea and vomiting may be manifestations of gastroparesis; <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> is often used to treat these cases. (See  <a class="medical medical_review" href="/z/d/html/2532.html" rel="external">"Treatment of gastroparesis", section on 'Metoclopramide'</a>.)</p><p class="headingAnchor" id="H3805717698"><span class="h3">Routine laboratory tests and evaluation for comorbidities</span><span class="headingEndMark"> — </span>As part of, or in addition to, the routine prenatal laboratory tests and evaluation obtained in the general obstetric population (see  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment", section on 'Laboratory tests'</a>), pregnant patients with diabetes should have the evaluations listed in the table  (<a class="graphic graphic_table graphicRef51463" href="/z/d/graphic/51463.html" rel="external">table 2</a>) and described below.</p><p class="headingAnchor" id="H1270733288"><span class="h4">Glycated hemoglobin</span><span class="headingEndMark"> — </span>A glycated hemoglobin concentration (A1C) is obtained at the initial prenatal visit. In the absence of significant red blood cell abnormalities, A1C reflects the patient's average level of glycemic management over the prior few weeks to months and thus assists in counseling about the risks of early pregnancy loss, congenital malformations, preeclampsia, and other complications. However, a glycemia-independent decline of A1C typically occurs during pregnancy [<a href="#rid11">11</a>], so the reliability of the A1C level to reflect early-pregnancy glycemia may depend on the gestational age at measurement. (See  <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Glycated hemoglobin (A1C)'</a> and  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a>.) </p><p>Some clinicians, including the authors, recheck A1C throughout gestation as an additional marker of glycemic control (beyond the primary method of blood glucose self-monitoring or continuous glucose monitoring), as A1C is strongly correlated with the risk of adverse pregnancy outcomes [<a href="#rid12">12,13</a>]. Due to alterations in red blood cell production and turnover during pregnancy, an A1C can be obtained as frequently as monthly [<a href="#rid14">14</a>]; our practice is to obtain an A1C every 6 to 10 weeks.</p><p class="headingAnchor" id="H3330315467"><span class="h4">Assessment of renal function and urine protein excretion</span><span class="headingEndMark"> — </span>Nephropathy is a cardinal microvascular complication of diabetes; small amounts of proteinuria (microalbuminuria) indicate glomerular damage and precede the development of a decline in glomerular filtration rate. Many patients with preexisting diabetes may have unrecognized subclinical glomerular damage; thus, a serum creatinine along with quantification of urinary proteinuria should be obtained at the first prenatal visit.</p><p>The authors prefer to obtain a 24-hour collection to assess both urine protein and creatinine; this allows for direct comparison with collections that may be obtained later in pregnancy for preeclampsia evaluation. However, the quantification of urine protein can be performed on a random urine sample using the urinary protein-to-creatinine ratio, which is both reproducible and more convenient for the patient than a 24-hour collection. (See  <a class="medical medical_review" href="/z/d/html/4808.html" rel="external">"Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome"</a>.)</p><p>Chronic kidney disease increases the risk of adverse maternal and fetal outcomes  (<a class="graphic graphic_table graphicRef118868" href="/z/d/graphic/118868.html" rel="external">table 3</a>) and the risk increases as the glomerular filtration rate declines. Evaluation and management of patients with nephropathy and outcomes of these pregnancies are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H959153743"><span class="h4">Dilated, comprehensive eye examination</span><span class="headingEndMark"> — </span>This retinal examination should be performed by an ophthalmologist. Close follow-up is indicated during pregnancy, with the frequency determined by baseline findings. The American Diabetes Association (ADA) suggests eye examinations prepregnancy, in all three trimesters, and for one year postpartum, as indicated by degree of retinopathy and as recommended by the eye care provider [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/1773.html" rel="external">"Diabetic retinopathy: Prevention and treatment", section on 'Pregnancy'</a>.)</p><p class="headingAnchor" id="H3472776038"><span class="h4">Clinical assessment for atherosclerotic vascular disease</span><span class="headingEndMark"> — </span>Diabetes is associated with an increased risk of atherosclerotic vascular disease. An electrocardiogram (ECG) is indicated in individuals starting at age 35 years who have cardiac signs/symptoms or risk factors and, if abnormal, further evaluation should be performed [<a href="#rid14">14</a>]. Referral to a cardiologist is appropriate for patients with cardiac symptoms, regardless of the ECG result. </p><p>An ECG can be considered in asymptomatic patients, particularly if not previously performed, though its value in those under age 40 without symptoms or other cardiovascular risk factors has not been established. (See  <a class="medical medical_review" href="/z/d/html/1551.html" rel="external">"Screening for coronary heart disease in patients with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H558833078"><span class="h4">Clinical assessment for neuropathy and gastroparesis</span><span class="headingEndMark"> — </span>The main symptoms of diabetic polyneuropathy are numbness, tingling, pain, and weakness, starting distally in the toes and feet; the symptoms are usually worse at night. Cranial and peripheral mononeuropathies can also occur. Gastroparesis is an autonomic neuropathy and may be confused with nausea and vomiting of pregnancy. Evaluation and management of these comorbidities are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5275.html" rel="external">"Epidemiology and classification of diabetic neuropathy"</a> and  <a class="medical medical_review" href="/z/d/html/5280.html" rel="external">"Management of diabetic neuropathy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2643.html" rel="external">"Diabetic autonomic neuropathy of the gastrointestinal tract", section on 'Gastroparesis'</a> and  <a class="medical medical_review" href="/z/d/html/2532.html" rel="external">"Treatment of gastroparesis"</a>.)</p><p></p><p class="headingAnchor" id="H1766654075"><span class="h4">Blood pressure measurement/management</span><span class="headingEndMark"> — </span>Chronic hypertension is a common comorbid condition in individuals with diabetes. In the absence of prepregnancy recent normal blood pressure measurements, hypertension prior to 20 weeks of gestation suggests chronic hypertension rather than a hypertensive disorder of pregnancy (eg, preeclampsia, gestational hypertension).</p><p>We suggest an upper blood pressure limit of &lt;140/90 mmHg for pregnant patients with diabetes, based on data from the 2022 Chronic Hypertension and Pregnancy (CHAP) trial [<a href="#rid15">15</a>] and in agreement with guidelines from the American College of Obstetricians and Gynecologists (ACOG) [<a href="#rid16">16</a>]. Data supporting the lower blood pressure limit to minimize the risk of placental underperfusion and, in turn, concern for impaired fetal growth are less clear. We believe it is reasonable to target the lower limit of blood pressure to ≥110/80 mmHg based on current ADA and ACOG guidelines and we would avoid blood pressures &lt;90/60 mmHg. The ADA suggests a blood pressure target of 110 to 135/85 mmHg [<a href="#rid14">14</a>]. </p><p>High-quality evidence supporting specific blood pressure targets in pregnant patients with chronic hypertension and diabetes is limited. </p><p class="bulletIndent1"><span class="glyph">●</span>The CHAP trial evaluated treatment of mild chronic hypertension during pregnancy (defined by blood pressure ≥140/90 mmHg before 20 weeks of gestation or on antihypertensive therapy with a single medication) [<a href="#rid15">15</a>]. The 2408 participants included 380 with diabetes (16 percent). Participants were randomly assigned to a blood pressure goal of &lt;140/90 mmHg (active treatment group) or to usual care (control group) where antihypertensive therapy was withheld or stopped at randomization unless severe hypertension developed (systolic pressure ≥160 mmHg or diastolic pressure ≥105 mmHg). Participants in the control group who went on to develop severe hypertension were begun on antihypertensive therapy and the goal blood pressure was also &lt;140/90 mmHg.</p><p></p><p class="bulletIndent1">Treatment to a goal &lt;140/90 mmHg reduced the risk of the composite primary outcome (severe preeclampsia, preterm birth at &lt;35 weeks of gestation, placental abruption, fetal or neonatal death) (30.2 versus 37.0 percent, adjusted risk ratio [aRR] 0.82, 95% CI 0.74-0.92) without significantly increasing the risk of small for gestational age birth weight (11.2 versus 10.4 percent, aRR 1.04, 95% CI 0.82-1.31). The composite risk reduction was similar for participants with versus without diabetes (RR 0.75 in those with diabetes); the risk of small for gestational age birth weight safety outcome was not reported separately for participants with diabetes. </p><p></p><p><a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">Labetalol</a> and extended-release <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> are antihypertensive drugs commonly used in pregnancy. Antihypertensive drug choice and dosing in pregnancy are reviewed in detail separately (see  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients"</a>). Use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) should be avoided in pregnancy because of adverse fetal/neonatal effects. (See  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a>.)</p><p class="headingAnchor" id="H3508765956"><span class="h4">Body mass index (BMI) assessment</span><span class="headingEndMark"> — </span>All pregnant patients should be counseled regarding the Institute of Medicine (IOM, now the National Academy of Medicine) weight gain recommendations, which are stratified and inversely related to preconception BMI. </p><p>Overweight BMI and obesity are common in patients with diabetes, particularly type 2 diabetes. Even in type 1 diabetes, insulin treatment itself can lead to weight gain. Clinicians caring for patients with both obesity and diabetes should be mindful of the potential morbidities of each condition, including adverse pregnancy outcome (eg, cesarean and preterm birth, fetal anomalies, large for gestational age [LGA] or macrosomic birth weight) and other health consequences [<a href="#rid17">17-20</a>]. Appropriate gestational weight gain is important for these individuals because gestational weight gain above IOM recommendations amplifies these risks and contributes to postpartum weight retention [<a href="#rid21">21-25</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Calorie requirements'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/441.html" rel="external">"Gestational weight gain"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a>.)</p><p></p><p class="headingAnchor" id="H2988957278"><span class="h4">Thyroid-stimulating hormone in patients with type 1 diabetes</span><span class="headingEndMark"> — </span>The prevalence of autoimmune thyroid dysfunction is increased in patients with type 1 diabetes. If thyroid-stimulating hormone (TSH) levels are elevated, thyroid peroxidase status is also checked. (See  <a class="medical medical_review" href="/z/d/html/5823.html" rel="external">"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus", section on 'Thyroid surveillance'</a>.)</p><p class="headingAnchor" id="H2864767343"><span class="h4">Urine culture</span><span class="headingEndMark"> — </span>While assessment for and treatment of asymptomatic bacteriuria is part of routine prenatal care, it is particularly important in patients with diabetes because of a three- to fivefold greater propensity for asymptomatic bacteriuria in these patients. Treatment and follow-up of patients with asymptomatic bacteriuria are reviewed separately, and are the same in patients with versus without diabetes. (See  <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">"Urinary tract infections and asymptomatic bacteriuria in pregnancy", section on 'Asymptomatic bacteriuria'</a>.)</p><p class="headingAnchor" id="H140160327"><span class="h3">Nonglycemic pharmacotherapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Folic acid</strong> – Patients with diabetes should consume at least 400 mcg of <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> daily to reduce the risk of neural tube defects (NTDs). Ideally, folic acid supplementation is begun prior to conception and continued throughout pregnancy. Higher doses of 1 to 5 mg daily, beginning before conception and continuing for the initial 12 weeks of gestation have sometimes been recommended. These data are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation", section on 'Folic acid supplementation for preventing NTDs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-dose </strong><strong>aspirin</strong><strong> </strong>– Pregestational diabetes is a risk factor for developing preeclampsia (pooled rate 11 percent, 95% CI 8.4-13.8 percent; pooled relative risk [RR] 3.7, 95% CI 3.1-4.3 [<a href="#rid26">26</a>]). The United States Preventive Services Task Force, ADA, and ACOG recommend that patients at high risk for preeclampsia, including all those with type 1 and type 2 diabetes, begin low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> after 12 weeks of gestation [<a href="#rid14">14,27,28</a>].</p><p></p><p class="bulletIndent1">Many providers, including the authors, prescribe 81 mg daily as is recommended by ACOG and the Society for Maternal-Fetal Medicine based on the results of a meta-analysis suggesting that lower doses are less effective [<a href="#rid29">29</a>], whereas the ADA recommends 100 to 150 mg daily [<a href="#rid14">14</a>]. Because a 100 or 150 mg dose is not available in the United States, the ADA states that a dose of 162 mg/day may be acceptable.</p><p></p><p class="bulletIndent1">Data regarding efficacy and dosing of low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for prevention of preeclampsia are reviewed separately. Trials have included few patients with diabetes, so the effectiveness of this intervention is unclear in this population [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Low-dose aspirin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antihypertensive therapy</strong> – Ideally, patients receiving angiotensin-converting enzyme (ACE) inhibitors or receptor blockers for hypertension or nephropathy should have been taken off these medications prior to pregnancy because of their teratogenic potential. If not discontinued prior to pregnancy, they should be suspended during pregnancy. The risks of these drugs in pregnancy are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a>.)</p><p></p><p class="bulletIndent1">Appropriate drug choices and goal blood pressure are discussed above. (See <a class="local">'Blood pressure measurement/management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination</strong> – Adults with diabetes are at increased risk from respiratory infection and should receive the pneumococcal vaccine as well as other standard vaccinations (eg, influenza vaccine, COVID-19).</p><p></p><p class="bulletIndent1">More information on vaccination during pregnancy is available separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/15870.html" rel="external">"Seasonal influenza and pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/127535.html" rel="external">"COVID-19: Overview of pregnancy issues", section on 'Vaccination in people planning pregnancy and pregnant or recently pregnant people'</a>.)</p><p></p><p class="headingAnchor" id="H1644543800"><span class="h2">Fetal issues</span></p><p class="headingAnchor" id="H4122939560"><span class="h3">Congenital anomalies/early pregnancy loss</span><span class="headingEndMark"> — </span>We inform patients with diabetes of the increased risk of congenital anomalies, including neural tube and cardiac anomalies [<a href="#rid31">31</a>], and provide more detailed discussion if A1C is markedly elevated. We explain that information about fetal development will be obtained from second-trimester fetal sonographic examination and, if performed, first-trimester ultrasound and maternal serum alpha-fetoprotein (MSAFP) results. (See <a class="local">'Screening for neural tube defects'</a> below and <a class="local">'Screening for other congenital anomalies'</a> below.)</p><p>Data from multiple studies have shown a higher risk of major congenital malformations and early pregnancy loss associated with increasing first-trimester A1C values  (<a class="graphic graphic_figure graphicRef67498" href="/z/d/graphic/67498.html" rel="external">figure 1</a>) [<a href="#rid32">32-35</a>]. Although A1C values from different laboratories may not have been comparable at the times these studies were conducted because of differences in methodology and a lack of standardization among laboratories, a value &gt;1 percent above the upper limit of the normal range is associated with an increased risk of congenital anomalies. </p><p>Data on the relationship between A1C and congenital anomalies/early pregnancy loss are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a> and  <a class="medical medical_review" href="/z/d/html/1807.html" rel="external">"Measurements of chronic glycemia in diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H2979713620"><span class="h3">Ultrasound examination</span><span class="headingEndMark"> — </span>First-trimester ultrasound has several benefits:</p><p class="bulletIndent1"><span class="glyph">●</span>Documentation of fetal cardiac activity is reassuring as the rate of early pregnancy loss is higher in patients with diabetes, especially those with uncontrolled hyperglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirmation or readjustment of the estimated date of delivery is important because many of these pregnancies undergo scheduled delivery or have accelerated or, less commonly, restricted fetal growth in the late second or the third trimester. (See  <a class="medical medical_review" href="/z/d/html/5391.html" rel="external">"Prenatal assessment of gestational age, date of delivery, and fetal weight"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some major congenital abnormalities (eg, anencephaly) can be detected in the late first trimester by a detailed fetal anatomic survey using a transvaginal transducer. Sensitivity is lower earlier in gestation because of difficulty in visualizing small structures and because some abnormalities of organs, such as the gastrointestinal tract, brain, and kidney, can be visualized better in the more physiologically advanced fetus. In particular, the fetal heart, which is a common site of diabetic embryopathy, is optimally visualized in the second trimester at 18 to 22 weeks. (see  <a class="medical medical_review" href="/z/d/html/5388.html" rel="external">"Overview of ultrasound examination in obstetrics and gynecology", section on 'Obstetric sonography'</a>)</p><p></p><p class="headingAnchor" id="H2055572045"><span class="h3">Screening for aneuploidy</span></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal diabetes mellitus is <strong>not</strong> a risk factor for aneuploidy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with diabetes are offered prenatal screening and diagnosis for aneuploidy and other genetic conditions according to practices in use for the general obstetric population. First-trimester serum and ultrasound markers of aneuploidy are not affected by maternal diabetes, in contrast to the second-trimester quadruple test. Noninvasive screening using cell-free DNA is thought not to be affected by maternal diabetes, though low fetal fraction can be seen in patients with obesity. (See  <a class="medical medical_review" href="/z/d/html/426.html" rel="external">"Down syndrome: Overview of prenatal screening"</a> and  <a class="medical medical_review" href="/z/d/html/458.html" rel="external">"Prenatal screening for common aneuploidies using cell-free DNA"</a>.)</p><p></p><p class="headingAnchor" id="H663749745"><span class="h1">SECOND TRIMESTER</span><span class="headingEndMark"> — </span>Prenatal visits are scheduled every two to four weeks through the second trimester, but more frequently if complications arise or glycemic management is suboptimal. This schedule of visits should be individualized based upon the severity of the diabetes, the degree of glycemic control, and the presence of other pregnancy complications.</p><p class="headingAnchor" id="H1443965360"><span class="h2">Maternal issues</span></p><p class="headingAnchor" id="H2718075158"><span class="h3">Glycemic management</span><span class="headingEndMark"> — </span>Glucose self-monitoring and targets are the same throughout pregnancy, though insulin requirements vary considerably. Close follow-up for glycemic control is especially important after 18 weeks of gestation, as insulin resistance resulting from placental hormones increases rapidly and, consequently, insulin requirements can rise quickly after this point [<a href="#rid9">9</a>]. Some programs review blood glucose values remotely via phone or electronic communication and will make needed insulin adjustments outside of in-person visits. (See  <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control"</a>.)</p><p class="headingAnchor" id="H178707986"><span class="h3">Preeclampsia</span><span class="headingEndMark"> — </span>Hypertensive disorders of pregnancy, including preeclampsia, are increased in patients with pregestational diabetes. The increased risk is likely related to both pregestational vascular disease (hypertension, nephropathy) and hyperglycemia itself [<a href="#rid36">36</a>].</p><p>The magnitude of risk is shown in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study that documented A1C values before and during pregnancy, the risk of preeclampsia increased significantly with increasing A1C values above optimal levels [<a href="#rid36">36</a>]. Compared with A1C &lt;6.1 percent at 26 weeks of gestation, the increased odds of preeclampsia with A1C 6.1 to 6.9 percent, 7.0 to 7.9 percent, and ≥8.0 percent were 2.1, 3.2, and 3.8, respectively. At 34 weeks of gestation, the increased odds of preeclampsia with A1C ≥7.0 and ≥8.0 percent were 3.3 and 8.0, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 462 patients with pregestational diabetes, the rate of preeclampsia in patients with White classification B, C, D, and F/R  (<a class="graphic graphic_table graphicRef79735" href="/z/d/graphic/79735.html" rel="external">table 1</a>) was 11, 22, 21, and 36 percent, respectively [<a href="#rid37">37</a>]. The increased risk of preeclampsia with more long-standing disease is explained in part by the observation that impaired endothelium-dependent vasodilation appears to be related to the duration of diabetes [<a href="#rid38">38</a>].</p><p></p><p>Monitoring for preeclampsia is a routine component of prenatal care and preeclampsia prophylaxis with low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is indicated in patients at high risk, such as those with pregestational diabetes. Diagnosis and management of preeclampsia are similar to that in patients without diabetes, except among those who enter pregnancy with preexisting hypertension or proteinuria; in these patients, the diagnosis can be difficult and requires relying on other markers. (See  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a> and  <a class="medical medical_review" href="/z/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis"</a>.)</p><p class="headingAnchor" id="H1325245787"><span class="h2">Fetal issues</span></p><p class="headingAnchor" id="H3549712472"><span class="h3">Screening for aneuploidy</span><span class="headingEndMark"> — </span>If screening/diagnosis was not performed in the first trimester, patients with diabetes are offered prenatal screening/diagnosis of aneuploidy and other genetic conditions according to practices in use for the general obstetric population. (See  <a class="medical medical_review" href="/z/d/html/426.html" rel="external">"Down syndrome: Overview of prenatal screening"</a>.)</p><p>Diabetes does <strong>not</strong> increase the risk of fetal aneuploidy. However, levels of maternal serum alpha-fetoprotein (MSAFP), unconjugated estriol (uE3), and inhibin A, which are components of some second-trimester Down syndrome screening tests, are significantly reduced in patients with diabetes, thereby mimicking the pattern suggestive of Down syndrome. Therefore, the laboratory requisition for biochemical marker screening should indicate that the patient has diabetes and the laboratory staff should adjust the multiples of the median (MoM) value accordingly. (See  <a class="medical medical_review" href="/z/d/html/414.html" rel="external">"Maternal serum marker screening for Down syndrome: Levels and laboratory issues", section on 'Diabetes mellitus'</a>.)</p><p class="headingAnchor" id="H1236969470"><span class="h3">Screening for neural tube defects</span><span class="headingEndMark"> — </span>The prevalence of neural tube defects (NTDs) is higher in pregnancies complicated by pregestational diabetes mellitus. As an example, in a study from 1982 (before recommendations for <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> supplementation and food fortification), NTDs occurred in 2 percent of pregnancies complicated by diabetes versus 0.1 to 0.2 percent of the general population [<a href="#rid39">39</a>]. In a study from 2004, NTDs occurred in 0.19 percent of pregnancies complicated by diabetes versus 0.07 percent of pregnancies without diabetes [<a href="#rid40">40</a>]. The lower prevalence in 2004 likely reflects trends in better periconceptional glucose control as well as increased periconceptional folic acid exposure.</p><p>We use ultrasound alone to screen for NTDs, but it may be used in combination with measurement of MSAFP. Since the median MSAFP level is 15 percent lower and the prevalence of NTDs is higher in pregnancies with diabetes than in those without diabetes, a lower threshold MSAFP value (eg, approximately 1.5 MoM) has typically been used in pregnancies with diabetes to obtain the same negative predictive value for NTDs as in those without diabetes. Laboratory requisitions for MSAFP typically ask providers to indicate if the patient has diabetes; however, the need for correction for diabetes independent of maternal weight has been challenged [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/460.html" rel="external">"Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management"</a>.)</p><p class="headingAnchor" id="H2370024677"><span class="h3">Screening for other congenital anomalies</span><span class="headingEndMark"> — </span>A detailed ultrasound examination of fetal anatomy is performed between 18 and 22 weeks of gestation; this is particularly important because of the increased prevalence of congenital anomalies in patients with diabetes. If the sonologist performing the ultrasound is aware of the diagnosis of diabetes, they can be particularly mindful of evaluating for anomalies common to such pregnancies  (<a class="graphic graphic_table graphicRef108112" href="/z/d/graphic/108112.html" rel="external">table 4</a>). Early detection of congenital anomalies allows parents and clinicians to prepare for the birth of an infant who may require specialized care. Alternatively, some parents may choose pregnancy termination; such procedures are more easily and safely performed at earlier gestational ages. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital heart disease</strong> – The heart is another focus of the fetal anatomy examination, which should include a four-chamber view and visualization of the outflow tracts. Detailed examination of the heart is important because congenital heart disease occurs more frequently in offspring of mothers with diabetes than in the general population and accounts for approximately one-half of diabetes-related major congenital anomalies [<a href="#rid31">31,42</a>]. As an example, in a series of 535 pregnant patients with preexisting diabetes, 30 (5.6 percent) gave birth to an infant with confirmed congenital heart disease; the rate was 8.3 percent in those with an A1C ≥8.5 percent versus 3.9 percent of those with an A1C below this level [<a href="#rid43">43</a>].</p><p class="bulletIndent1">Some centers refer all patients with diabetes for fetal echocardiograms, while others restrict echocardiography to pregnancies at high risk, such as those with either abnormalities on imaging the four chambers and outflow tracts or elevated periconception/first-trimester A1C (eg, ≥8 percent in our practice). A selective approach is often acceptable because routine echocardiography detects few additional malformations in centers with high-volume, skilled, detailed obstetric ultrasound services [<a href="#rid44">44,45</a>]. (See  <a class="medical medical_review" href="/z/d/html/6755.html" rel="external">"Congenital heart disease: Prenatal screening, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1">Conotruncal and ventricular septal defects are the most common cardiac anomalies in infants of mothers with diabetes. Significant augmentation of interventricular septal thickness may be noted in midtrimester fetuses of these pregnancies and often progresses during the course of pregnancy [<a href="#rid46">46</a>]. The hypertrophy primarily occurs in pregnancies with uncontrolled hyperglycemia. Although this condition is usually mild and asymptomatic in the neonate, congestive cardiomyopathy, which is a more diffuse process of hypertrophy and hyperplasia of the myocardial cells, can also occur. Both disorders are transient and managed with supportive care. (See  <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)", section on 'Ventricular hypertrophy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall diagnostic performance</strong> – The performance of ultrasound for prenatal detection of congenital anomalies was illustrated in a retrospective study of pregnant patients with pregestational diabetes who received detailed sonography with fetal echocardiography at 18 to 22 weeks in one hospital system and subsequently gave birth to a liveborn or stillborn between 2011 and 2017 [<a href="#rid47">47</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Major anomalies were present in 7 percent of newborns</p><p class="bulletIndent2"><span class="glyph">•</span>76 percent of the anomalies were detected prenatally</p><p class="bulletIndent2"><span class="glyph">•</span>68 percent of the prenatally-detected anomalies were identified during the initial detailed fetal sonogram with echocardiography; another 8 percent were identified on follow-up sonography</p><p class="bulletIndent2"><span class="glyph">•</span>Prenatal detection by organ system was over 85 percent for central nervous system, genitourinary, and musculoskeletal anomalies; 65 percent for cardiac anomalies; and 43 percent for craniofacial anomalies</p><p></p><p class="headingAnchor" id="H11"><span class="h1">THIRD TRIMESTER</span><span class="headingEndMark"> — </span>In the third trimester, prenatal visits are as often as every one to two weeks until 36 weeks of gestation, and then weekly until birth. Depending on gestational age, fetal testing may occur more frequently.</p><p class="headingAnchor" id="H1876193230"><span class="h2">Maternal issues</span></p><p class="headingAnchor" id="H2573151044"><span class="h3">Glycemic management</span><span class="headingEndMark"> — </span>Glucose self-monitoring and targets are the same throughout pregnancy. Continued control of blood glucose concentration during the third trimester is important to minimize the risk of fetal complications, such as accelerated growth, neonatal metabolic and physiologic disturbances, and stillbirth. Although accelerated growth and neonatal hypoglycemia remain common, third-trimester fetal demise is now rare in pregnancies complicated by diabetes, primarily because of better glycemic control. As in the late second trimester, frequent escalation of insulin doses is commonly required to maintain euglycemia, but insulin requirements generally plateau by 37 weeks of gestation and may decline slightly. A ≥15 percent decline in insulin requirements should prompt evaluation of fetal well-being. (See  <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Insulin requirements in pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Implications of falling insulin requirement'</a>.)</p><p class="headingAnchor" id="H391317201"><span class="h3">Asymptomatic bacteriuria</span><span class="headingEndMark"> — </span>Rescreening for asymptomatic bacteriuria with urine culture at the start of the third trimester is reasonable in patients who did not have bacteriuria on the initial test because they remain at high risk for developing bacteriuria. </p><p class="headingAnchor" id="H1727799793"><span class="h3">Preeclampsia</span><span class="headingEndMark"> — </span>Close monitoring for the development of hypertensive disorders of pregnancy (eg, preeclampsia, gestational hypertension, HELLP syndrome) is continued in the third trimester. (See <a class="local">'Preeclampsia'</a> above.)</p><p class="headingAnchor" id="H3744117740"><span class="h3">Preterm birth</span><span class="headingEndMark"> — </span>Compared with controls without diabetes or hypertension, patients with pregestational diabetes have higher rates of both indicated preterm birth (22 versus 3 percent, odds ratio [OR] 8.1, 95% CI 6.0-10.9) and spontaneous preterm birth (16 versus 11 percent, OR 1.6, 95% CI 1.2-2.2) [<a href="#rid48">48</a>]. Indicated preterm birth is primarily initiated because of preeclampsia [<a href="#rid48">48,49</a>], but both gestational and pregestational diabetes have been associated with indicated preterm birth independent of preeclampsia. The reasons for an increased risk of spontaneous preterm birth are not clear [<a href="#rid50">50,51</a>].</p><p>The indications for inhibition of preterm labor are similar to those in the general obstetric population. Our preferences for tocolytic therapy are <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> or <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> (for pregnancies less than 32 weeks of gestation). We avoid beta-adrenergic receptor agonists as they can cause severe hyperglycemia in patients with diabetes. (See  <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">"Inhibition of acute preterm labor"</a>.)</p><p class="headingAnchor" id="H1713768908"><span class="h4">Antenatal glucocorticoids in patients at risk for preterm birth</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Up to 33+6 weeks</strong> – If preterm birth of a potentially viable neonate ≤33+6 weeks of gestation is anticipated or planned, administration of <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> improves neonatal outcome, but close maternal glucose monitoring is essential. Transient hyperglycemia induced by glucocorticoids can be severe in patients with diabetes, even when glucose levels are closely monitored and treated [<a href="#rid52">52,53</a>]. The hyperglycemic effect begins approximately 12 hours after the first steroid dose and lasts for approximately five days [<a href="#rid54">54,55</a>]. In a series in which 16 patients with type 1 diabetes requiring insulin therapy were given betamethasone for fetal lung maturation, the insulin dose for the following five days increased by 6, 38, 36, 27, and 17 percent above baseline, respectively [<a href="#rid54">54</a>]. Our clinical experience has been that patients with insulin resistance or obesity may experience even greater increases in insulin requirement after steroid administration. </p><p></p><p class="bulletIndent1">We preemptively increase subcutaneous insulin doses in patients receiving <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a>, starting with the algorithm suggested by Mathiesen et al [<a href="#rid54">54</a>] and using additional correctional subcutaneous insulin along with rapid titration as needed. Capillary blood glucose concentrations are checked one to two hours before and after meals and at bedtime. Steroid administration, subsequent glucose monitoring, and management of glycemia is typically performed in hospitalized patients, but the process could be conducted in nonhospitalized patients who are able to closely monitor their glucose levels, promptly communicate with their providers, and adjust insulin doses accordingly.</p><p></p><p class="bulletIndent1">In the Mathiesen et al algorithm for initial dosing, increments of insulin dose are related to the insulin dose at baseline (ie, on the day before the first <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> injection is administered):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Day 1 (first day of <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a>) – Increase the bedtime insulin dose by 25 percent over the baseline dose</p><p class="bulletIndent2"><span class="glyph">•</span>Day 2 and day 3 – Increase all insulin doses to 40 percent over the baseline dose</p><p class="bulletIndent2"><span class="glyph">•</span>Day 4 – Decrease all insulin doses to 20 percent over the baseline dose </p><p class="bulletIndent2"><span class="glyph">•</span>Day 5 – Decrease all insulin doses to 10 percent over the baseline dose. </p><p class="bulletIndent2"><span class="glyph">•</span>Day 6 – Decrease insulin doses to the level before the <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> treatment</p><p></p><p class="bulletIndent1">We initiate a continuous intravenous insulin infusion on the labor unit if values are persistently elevated despite escalation of the subcutaneous regimen or if initial values are above 180 mg/dL (10.0 mmol/L). (See  <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on '23+0 to 33+6 weeks'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>34+0 and 36+6 weeks</strong> – Although administration of <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> also had potential benefits before preterm births between 34+0 and 36+6 weeks of gestation in a randomized trial (Antenatal Betamethasone for Women at Risk for Late Preterm Delivery [<a href="#rid56">56</a>]), patients with diabetes were specifically excluded from this trial, and, concordant with recommendations from specialty societies [<a href="#rid57">57</a>], we suggest not administering steroids to improve neonatal outcome in diabetic pregnancies at late preterm gestational ages. (See  <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on '34+0 or more weeks'</a>.)</p><p></p><p class="headingAnchor" id="H4057872520"><span class="h2">Fetal issues</span></p><p class="headingAnchor" id="H1597525564"><span class="h3">Risk of stillbirth</span><span class="headingEndMark"> — </span>Patients with pregestational diabetes have a fivefold increased risk of stillbirth compared to those without diabetes [<a href="#rid58">58</a>]. The pathophysiology appears to be multifactorial, and may include congenital anomalies and fetal effects from maternal hyperglycemia and vascular disease (including preeclampsia):</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal hyperglycemia and hyperinsulinemia increase fetal oxygen consumption, which may induce fetal hypoxemia and acidosis if the oxygen needs of the fetus are not met [<a href="#rid59">59-63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal vasculopathy and hyperglycemia can lead to reduced uteroplacental perfusion, which may be associated with reduced fetal growth [<a href="#rid64">64</a>].</p><p></p><p class="headingAnchor" id="H2417196371"><span class="h4">Initiation and frequency of fetal surveillance</span><span class="headingEndMark"> — </span>We begin twice-weekly antepartum surveillance (eg, nonstress test, biophysical profile) at 32 weeks of gestation to reduce the risk of stillbirth, in line with guidance from the American College of Obstetricians and Gynecologists (ACOG) [<a href="#rid65">65</a>]. In complicated pregnancies with fetal growth restriction, oligohydramnios, preeclampsia, or uncontrolled hyperglycemia, testing may start as early as 26 weeks of gestation. Any significant deterioration in maternal status or a ≥15 percent decline in insulin requirements necessitates reevaluation of the fetus. The frequency of fetal death (excluding fetuses with congenital malformations) with such protocols is approximately 3 per 1000 pregnancies in patients with type 1 diabetes [<a href="#rid66">66</a>].</p><p>Nonreassuring test results:</p><p class="bulletIndent1"><span class="glyph">●</span>If nonreassuring fetal testing is related to a potentially reversible problem such as hyperglycemia or ketoacidosis, the fetus can often be resuscitated in utero by prompt correction of the mother's metabolic derangement. Pathologic fetal heart rate patterns will often revert to normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If nonreassuring fetal testing appears to be related to a nonreversible problem, the gestational age and the associated risk for sequelae of preterm birth strongly influence management. In preterm gestations, we try to delay delivery, at least long enough to treat the mother with <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> to accelerate fetal lung maturation (see <a class="local">'Antenatal glucocorticoids in patients at risk for preterm birth'</a> above). This can be done while monitoring the fetus more intensively or even continuously. The degree of compromise indicated by fetal surveillance helps to inform the relative risks and benefits of delaying delivery.</p><p></p><p>Although antepartum fetal testing is routinely performed in pregnancies complicated by pregestational diabetes [<a href="#rid28">28</a>], no data from large or randomized trials are available on which to base an evidence-based recommendation as to whether all or selected pregnancies complicated by diabetes should undergo fetal surveillance, when to start, what test to order, or how often to perform testing [<a href="#rid67">67</a>]. As a result, management is largely based on clinical experience and expert opinion and varies widely [<a href="#rid68">68</a>]. A National Institutes of Health workshop recognized the limitations of available data and concluded that, in managing pregnancies complicated by diabetes, it was "not clear which method [of antenatal testing], if any, is superior" [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H12667834"><span class="h3">Assessment of fetal growth</span><span class="headingEndMark"> — </span>Pregnancies complicated by maternal diabetes without vascular disease are often associated with accelerated growth [<a href="#rid70">70</a>]. Maternal vascular disease (including preeclampsia) increases the risk of impaired fetal growth [<a href="#rid4">4,71</a>].</p><p class="headingAnchor" id="H2559351478"><span class="h4">Initiation and frequency of growth measurements</span><span class="headingEndMark"> — </span>We obtain an ultrasound examination at 28 to 32 weeks of gestation to assess fetal growth. In the absence of impaired fetal growth, the examination is repeated every four weeks to evaluate growth and, as term approaches, to assist with birth plans. (See <a class="local">'Route'</a> below.)</p><p class="headingAnchor" id="H1752080810"><span class="h4">Accelerated fetal growth</span><span class="headingEndMark"> — </span>The risk of fetal overgrowth is strongly related to the degree of glycemic control [<a href="#rid72">72</a>], but prepregnancy obesity and gestational weight gain likely play a role as well [<a href="#rid73">73,74</a>]. Fetal overgrowth impacts intrapartum and neonatal outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span>Maternal diabetes dramatically increases the risk of large for gestational age (LGA) birth weight, which increases the risk for a prolonged second stage of labor, shoulder dystocia, operative delivery, maternal and infant birth trauma, and perinatal death [<a href="#rid75">75,76</a>]. The risk of stillbirth is particularly high at ≥35 weeks [<a href="#rid76">76</a>]. Maternal diabetes also changes fetal anthropometric measurements compared with offspring of mothers without diabetes [<a href="#rid77">77</a>]; specifically, the chest-to-head and shoulder-to-head ratios are increased in neonates of people with diabetes requiring insulin [<a href="#rid78">78</a>]. These changes increase the likelihood of shoulder dystocia two- to sixfold compared with the population without diabetes [<a href="#rid79">79</a>] and increase the likelihood of dystocia-associated fetal morbidity, such as brachial plexus injury [<a href="#rid80">80</a>]. The correlation between shoulder dystocia and birth weight in patients with and without diabetes is shown in the table  (<a class="graphic graphic_table graphicRef75719" href="/z/d/graphic/75719.html" rel="external">table 5</a>) [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/z/d/html/4472.html" rel="external">"Shoulder dystocia: Risk factors and planning birth of high-risk pregnancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Accelerated fetal growth is also associated with an increased risk of neonatal metabolic and physiologic disturbances. (See  <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)", section on 'Neonatal complications'</a>.)</p><p></p><p>If present, accelerated fetal growth often becomes apparent at 26 to 28 weeks of gestation, which is the rationale for an early third-trimester ultrasound examination [<a href="#rid42">42,82,83</a>]. However, some fetuses do not exhibit accelerated fetal growth until the later in the third trimester, which is the rationale for ongoing monitoring [<a href="#rid84">84</a>].</p><p>The diagnosis of accelerated fetal growth is based on identification of an LGA fetus, ie, greater than the<sup> </sup>90<sup>th</sup> percentile for fetuses of that gestational age (possibly including adjustments for fetal sex and ethnicity). At 40 weeks of gestation, the<sup> </sup>90<sup>th</sup> percentile for birth weight in the United States is approximately 4060 grams [<a href="#rid85">85</a>].</p><p>The term "macrosomia" is a type of LGA that refers to a fetus that is greater than some defined weight regardless of gestational age or sex. Various authors and professional organizations have defined macrosomia as &gt;4000, &gt;4250, and &gt;4500 grams. We use the ACOG threshold, which is &gt;4500 grams because maternal and neonatal morbidity increases sharply above this level [<a href="#rid86">86</a>].</p><p>There is no highly reliable method for identifying LGA fetuses before birth, even though neonatal weight is an important predictor of neonatal morbidity and estimation of fetal weight at term is an important variable in birth planning [<a href="#rid42">42,87,88</a>] (see <a class="local">'Route'</a> below). In a review of studies of ultrasound for predicting estimated fetal weight (EFW) &gt;4000 grams in patients with diabetes, sensitivity ranged from 33 to 83 percent and specificity ranged from 77 to 98 percent [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/4443.html" rel="external">"Fetal macrosomia", section on 'Patients with diabetes'</a>.)</p><p class="headingAnchor" id="H1061371172"><span class="h4">Growth restriction</span><span class="headingEndMark"> — </span>Growth restriction is most common in pregnancies with maternal vascular disease [<a href="#rid4">4,71</a>]. In one study including 53 patients with diabetic vascular disease, the frequencies of small and LGA newborns were 9 out of 53 and 4 out of 53, respectively [<a href="#rid4">4</a>]. The prenatal diagnosis, obstetric management, and outcome of fetal growth restriction are the same as in pregnancies without diabetes. (See  <a class="medical medical_review" href="/z/d/html/5062.html" rel="external">"Infants with fetal (intrauterine) growth restriction"</a> and  <a class="medical medical_review" href="/z/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome", section on 'Prenatal care'</a>.)</p><p class="headingAnchor" id="H3964899704"><span class="h3">Polyhydramnios</span><span class="headingEndMark"> — </span>Maternal diabetes is a common etiology of polyhydramnios. The mechanism for the increased amniotic fluid volume has not been clearly defined. Possibilities include fetal polyuria secondary to maternal and fetal hyperglycemia, decreased fetal swallowing, or an imbalance in water movement between the maternal and fetal compartments [<a href="#rid89">89</a>]. Polyhydramnios is frequently associated with accelerated fetal growth. (See  <a class="medical medical_review" href="/z/d/html/2283.html" rel="external">"Physiology of amniotic fluid volume regulation"</a>.)</p><p>Diabetes-associated polyhydramnios is rarely severe, thus it rarely requires intervention for severe maternal symptoms. Fetal outcomes are more favorable than in pregnancies in which polyhydramnios is associated with serious fetal disorders such as neurologic disease, twin-to-twin transfusion, or other syndromes [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/z/d/html/6781.html" rel="external">"Polyhydramnios: Etiology, diagnosis, and management in singleton gestations"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">DELIVERY</span></p><p class="headingAnchor" id="H1672298227"><span class="h2">Timing</span><span class="headingEndMark"> — </span>Timing is based on assessment of multiple factors, including gestational age, estimated fetal weight, and maternal glycemic control and comorbidities (eg, vascular disease<strong> </strong>or prior stillbirth).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients</strong> <strong>with well-controlled hyperglycemia and without macrosomia</strong>, we suggest delivery at 39+0 to 39+6 weeks of gestation. There is little maternal or newborn benefit and some potential harm in continuing pregnancy beyond 39 weeks. On the other hand, early-term (37+0 to 38+6 weeks) and late preterm (34+0 to 36+6 weeks) births are associated with increased newborn morbidity, even in patients without pregestational diabetes [<a href="#rid91">91,92</a>], and before 38.5 weeks of gestation, respiratory distress syndrome (RDS) is more likely to develop in infants of patients with diabetes than in those without diabetes because the endocrine changes associated with maternal diabetes delay fetal lung maturation [<a href="#rid93">93,94</a>]. Specifically, high fetal insulin levels enhance cellular hypertrophy and hyperplasia at the expense of cellular maturation, thus leading to macrosomia and immature lung function. In the era prior to the availability of fetal pulmonary maturity tests, RDS accounted for 52 percent of neonatal deaths among infants born to patients with pregestational diabetes [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients with impending macrosomia</strong>, we do not routinely induce patients before 39+0 weeks for this indication alone. Sonographic assessment of fetal weight is imprecise among fetuses &gt;4000 grams and there is no high-quality evidence establishing a clear benefit of early induction in this setting in pregnancies complicated by pregestational diabetes. Macrosomia is a factor in choosing the route of delivery. (See <a class="local">'Route'</a> below.)</p><p></p><p class="bulletIndent1">The largest randomized trial comparing the outcomes of induction versus expectant management of large for gestational age (LGA) fetuses specifically excluded patients with insulin-requiring diabetes. In this trial, 407 fetuses with estimated weight &gt;95<sup>th</sup> percentile at 36 to 38 weeks (ie, 3500 grams at 36 weeks of gestation, 3700 grams at 37 weeks, 3900 grams at 38 weeks) were induced between 37+0 and 38+6 weeks and within three days, and 411 were managed expectantly [<a href="#rid96">96</a>]. The likelihood of vaginal birth was 14 percent higher with induction (95% CI 1 to 29 percent). Induction reduced the risk of significant shoulder dystocia by 68 percent (95% CI 12 to 85 percent), but without a statistical difference between groups in the number of fetuses with a fracture (two in the induction group versus eight in the expectant management group) and no brachial plexus injuries occurred in either group. The induction group had higher proportions of infants with a high bilirubin concentration and receiving phototherapy group, which are some of the morbidities expected with births &lt;39+0 weeks of gestation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For selected patients, </strong>we<strong> </strong>plan delivery before 39+0 weeks:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For patients with</strong> <strong>uncontrolled hyperglycemia, vascular disease, or prior stillbirth</strong>, we suggest delivery at 36+0 to 38+6 weeks because of the risk of stillbirth, consistent with guidance from the American College of Obstetricians and Gynecologists (ACOG) [<a href="#rid97">97</a>]. The timing of delivery within this range and the route depend on patient-specific factors and preferences, and may be evaluated within a framework of shared decision-making, balancing the risk of stillbirth from continued expectant management against the respiratory morbidity associated with late-preterm or early-term birth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For patients with standard obstetric or medical indications for delivery</strong> (eg, preterm prelabor rupture of membranes, preeclampsia worsening maternal renal insufficiency or active proliferative retinopathy), delivery timing before 39+0 weeks and route are individualized, depending on the specific clinical scenario.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recommendations of others</strong> – As reflected above, ACOG and the Society for Maternal-Fetal Medicine recommend [<a href="#rid28">28,97,98</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with well-controlled glucose levels and no vascular disease: deliver at 39+0 to 39+6 weeks. Expectant management beyond 40+0 weeks is not recommended.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with uncontrolled hyperglycemia or vascular disease: deliver at 36+0 to 38+6 weeks (or even earlier if severity of complications warrants earlier delivery).</p><p></p><p class="headingAnchor" id="H24"><span class="h2">Route</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without macrosomia</strong> – Maternal diabetes alone is not an indication for cesarean birth in the absence of the usual obstetric indications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with macrosomia</strong> – Macrosomia can be an indication for cesarean birth due to the risk of morbidity from shoulder dystocia [<a href="#rid99">99-102</a>]. It has been suggested that neonates with shoulder dystocia have greater shoulder and chest-to-head disproportion than macrosomic infants without this complication [<a href="#rid78">78,103</a>]. In particular, macrosomic infants of mothers with diabetes are more likely to exhibit this disproportion than infants of comparable weight of nondiabetic mothers [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1">We agree with the ACOG that prophylactic cesarean birth is reasonable to prevent brachial plexus injury when the EFW is greater than 4500 grams in a patients with diabetes  (<a class="graphic graphic_table graphicRef75719" href="/z/d/graphic/75719.html" rel="external">table 5</a>), even though the diagnosis of macrosomia is imprecise [<a href="#rid28">28,104</a>]. If the patient has had a previous child with shoulder dystocia, then EFW, gestational age, and the severity of the prior neonatal injury, if any, should also be considered in making the decision about route of delivery [<a href="#rid105">105</a>]. (See  <a class="medical medical_review" href="/z/d/html/4472.html" rel="external">"Shoulder dystocia: Risk factors and planning birth of high-risk pregnancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients undergoing forceps- or vacuum-assisted vaginal birth</strong> – Since both diabetes and forceps- or vacuum-assisted vaginal birth are associated with an increased risk for shoulder dystocia, it is reasonable to perform a cesarean birth rather than an assisted vaginal birth in patients with diabetes, estimated fetal weight (EFW) &gt;4000 grams, and a prolonged second stage [<a href="#rid106">106</a>]. This decision should be individualized, taking into account factors such as the past obstetric history, estimated fetal weight, fetal position, and station. (See  <a class="medical medical_review" href="/z/d/html/4474.html" rel="external">"Assisted (operative) vaginal birth"</a> and  <a class="medical medical_review" href="/z/d/html/132063.html" rel="external">"Labor: Diagnosis and management of a prolonged second stage", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients undergoing a trial of labor after a previous cesarean birth</strong> – Maternal diabetes is not a contraindication to a trial of labor after a previous cesarean birth (TOLAC); however, the success rate may be lower than in patients without diabetes (64 versus 74 percent in one study [<a href="#rid107">107</a>]). (See  <a class="medical medical_review" href="/z/d/html/4479.html" rel="external">"Choosing the route of delivery after cesarean birth"</a>.)</p><p></p><p class="headingAnchor" id="H25"><span class="h2">Management</span><span class="headingEndMark"> — </span>Specific issues for managing patients with pregestational diabetes on the labor unit include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scheduling</strong> – When an induction or cesarean birth is indicated, we schedule the procedure early in the morning, when possible, as this facilitates management of glucose and insulin in a fasting patient. (See  <a class="medical medical_review" href="/z/d/html/4441.html" rel="external">"Pregestational (preexisting) and gestational diabetes: Intrapartum and postpartum glucose management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycemic management </strong>– Peripartum maintenance of maternal euglycemia is essential and generally requires hourly capillary glucose determinations, intravenous solutions containing dextrose, and intravenous or subcutaneous insulin if hyperglycemia is present. Management of glucose and insulin during labor, cervical ripening, induction, and cesarean birth is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4441.html" rel="external">"Pregestational (preexisting) and gestational diabetes: Intrapartum and postpartum glucose management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal monitoring</strong> – The fetal heart rate is continuously monitored on the labor and delivery unit, as these pregnancies are at increased risk for nonreassuring fetal heart rate patterns [<a href="#rid108">108,109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Analgesia and anesthesia</strong> – There are no contraindications to natural childbirth or neuraxial or general anesthesia. As in patients without diabetes, the choice of anesthetic technique should be based on patient and surgical factors, and intraoperative fluid boluses should consist of glucose-free solutions to prevent neonatal hypoglycemia. (See  <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)"</a> and  <a class="medical medical_review" href="/z/d/html/4468.html" rel="external">"Pharmacologic management of pain during labor and delivery"</a>.)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">POSTPARTUM</span></p><p class="headingAnchor" id="H4104505839"><span class="h2">Glycemic management</span><span class="headingEndMark"> — </span>Insulin requirements drop sharply after delivery and are substantially lower than requirements prior to pregnancy [<a href="#rid110">110</a>]. Glucose monitoring and insulin dosing in the postpartum period are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4441.html" rel="external">"Pregestational (preexisting) and gestational diabetes: Intrapartum and postpartum glucose management", section on 'Type 1 diabetes'</a>.)</p><p class="headingAnchor" id="H1190730722"><span class="h2">Maternal issues</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breastfeeding</strong> – Breastfeeding should be encouraged and supported [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/5013.html" rel="external">"Infant benefits of breastfeeding"</a> and  <a class="medical medical_review" href="/z/d/html/5022.html" rel="external">"Maternal and economic benefits of breastfeeding"</a>.)</p><p></p><p class="bulletIndent1">Both insulin and <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> are compatible with breastfeeding. Patients with type 1 diabetes who breastfeed may have a basal insulin requirement that is approximately 15 percent lower than prior to pregnancy and this reduction can persist for at least six months after birth [<a href="#rid111">111</a>]. </p><p></p><p class="bulletIndent1">Patients with diabetes appear to have more problems with lactation and may benefit from consultation with a lactation specialist. (See  <a class="medical medical_review" href="/z/d/html/4996.html" rel="external">"Common problems of breastfeeding and weaning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum depression</strong> – Postpartum depression appears to be more common among patients with diabetes (pregestational or gestational) than in patients without diabetes [<a href="#rid112">112</a>], so routine screening is especially important. The validated questionnaire most commonly used for screening pregnant and postpartum individuals is the Edinburgh Postnatal Depression Scale  (<a class="graphic graphic_figure graphicRef67741 graphicRef81407" href="/z/d/graphic/67741.html" rel="external">figure 2A-B</a>), but other validated tools can be used  (<a class="graphic graphic_table graphicRef59307" href="/z/d/graphic/59307.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/z/d/html/1704.html" rel="external">"Postpartum unipolar major depression: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraception</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without vascular disease</strong> – The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=4806" target="_blank">United States Medical Eligibility Criteria for Contraceptive Use</a> consider all hormonal methods acceptable for patients with diabetes and no vascular disease [<a href="#rid113">113</a>]; thus, selection should be based upon the same factors that apply to patients without diabetes (see  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>).</p><p></p><p class="bulletIndent2">Although evidence from randomized trials is limited, both progestin-only methods and low-dose combined oral contraceptives appear to have only minor effects on glucose and fat metabolism [<a href="#rid114">114</a>]. However, depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA) may increase blood glucose levels; therefore, patients with diabetes and no vascular disease who elect to use DMPA should carefully monitor their blood glucose levels [<a href="#rid115">115-117</a>]. (See  <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits"</a> and  <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with vascular disease</strong> – In patients with vascular disease, <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">DMPA</a> and combined estrogen-progestin contraceptives are generally avoided [<a href="#rid113">113</a>]. The progestin-releasing intrauterine device (IUD), <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">copper IUD</a>, and <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">etonogestrel implant</a> are highly effective contraceptive methods and have a lower risk of thromboembolic events than estrogen-progestin contraceptives [<a href="#rid118">118</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ophthalmologic follow-up</strong> – Ophthalmologic follow-up during the first year postpartum is advised since retinopathy can be aggravated during pregnancy or postpartum [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H1755783417"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109438.html" rel="external">"Society guideline links: Diabetes mellitus in pregnancy"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114691.html" rel="external">"Society guideline links: Shoulder dystocia and macrosomia"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/6722.html" rel="external">"Patient education: Care during pregnancy for patients with type 1 or 2 diabetes (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/6735.html" rel="external">"Patient education: Gestational diabetes (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycemic management </strong>– Meticulous attention to glycemic control throughout gestation is essential to minimize the risk of complications. Self-monitored glucose targets are (see <a class="local">'Glycemic management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fasting, preprandial, and nocturnal glucose 70 to 95 mg/dL (3.9 to 5.3 mmol/L)<strong> and</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One-hour postprandial glucose 110 to 140 mg/dL (6.1 to 7.8 mmol/L) <strong>or</strong></p><p class="bulletIndent3"><span class="glyph">-</span>Two-hour postprandial glucose 100 to 120 mg/dL (5.6 to 6.7 mmol/L)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients using continuous glucose monitoring, the target glucose range is 63 to 140 mg/dL (3.5 to 7.8 mmol/L), and the time in range goal is &gt;70 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insulin requirements across pregnancy</strong> – While glucose targets are the same throughout pregnancy, insulin requirements decrease in the first trimester so the risk for hypoglycemia increases. After 18 weeks of gestation, insulin requirements increase quickly until plateauing near 37 weeks of gestation. An unexpected ≥15 percent decline in insulin requirements should prompt an assessment of fetal well-being. (See  <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Insulin requirements in pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Implications of falling insulin requirement'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First trimester</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nausea and vomiting </strong>– We have a low threshold for treatment of nausea and vomiting of pregnancy as it facilitates insulin management and relieves maternal discomfort. Clinicians should also consider whether it may be a manifestation of gastroparesis. (See <a class="local">'Nausea and vomiting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maternal evaluation </strong>– In addition to routine prenatal assessments (see  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment"</a>), evaluations related to diabetes are listed in the table  (<a class="graphic graphic_table graphicRef51463" href="/z/d/graphic/51463.html" rel="external">table 2</a>). (See <a class="local">'Routine laboratory tests and evaluation for comorbidities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Noninsulin pharmacotherapy</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">Folic acid</a> (at least 400 mg orally daily) is begun prior to pregnancy or as soon as pregnancy is diagnosed for prevention of neural tube defects (NTDs). (See <a class="local">'Nonglycemic pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> 81 to 162 mg is begun at 12 weeks of gestation for preeclampsia prophylaxis (patients with diabetes are at increased risk for preeclampsia). (See <a class="local">'Nonglycemic pharmacotherapy'</a> above and <a class="local">'Preeclampsia'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with hypertension, we recommend a goal<strong> </strong>blood pressure of less than 140/90 mmHg. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers should be avoided. (See <a class="local">'Blood pressure measurement/management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fetal evaluation </strong>– First-trimester obstetric ultrasound is useful to confirm cardiac activity and gestational age, and provide preliminary evaluation for major congenital malformations because pregestational diabetes is associated with increased risks for pregnancy loss, congenital anomalies, and preterm birth. (See <a class="local">'Ultrasound examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second and third trimesters</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preeclampsia </strong>– Monitoring for preeclampsia is a routine component of prenatal care, but diagnosis may be more difficult in those with preexisting hypertension or proteinuria. (See  <a class="medical medical_review" href="/z/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fetal anatomic survey </strong>– Detailed ultrasound examination of fetal anatomy is performed between 18 and 22 weeks of gestation. Depending on local expertise, all patients with diabetes may be referred for fetal echocardiograms or echocardiography can be restricted to patients at high risk, such as those with abnormalities on imaging the four chambers and outflow tracts or elevated periconception A1C. (See <a class="local">'Screening for other congenital anomalies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antepartum fetal surveillance</strong> – Patients with pregestational diabetes are at increased risk of stillbirth. Twice-weekly antepartum fetal surveillance (nonstress test, biophysical profile) is begun at 32 weeks of gestation. (See <a class="local">'Initiation and frequency of fetal surveillance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assessment of fetal growth and amniotic fluid</strong> – We obtain an ultrasound examination at 28 to 32 weeks of gestation to assess for normal, accelerated, or restricted fetal growth, and repeat the examination every four weeks. Accelerated fetal growth and its complications (eg, shoulder dystocia) are common. Polyhydramnios, if present, is rarely severe. (See <a class="local">'Assessment of fetal growth'</a> above and <a class="local">'Polyhydramnios'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antenatal corticosteroids </strong>– If a course of antenatal corticosteroids is administered to patients at high risk for preterm birth, blood glucose concentrations are checked frequently and hyperglycemia, which may become severe, is managed with increased insulin. (See <a class="local">'Antenatal glucocorticoids in patients at risk for preterm birth'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tocolysis</strong> – Our preferences for tocolytic therapy are <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> or <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> (for pregnancies less than 32 weeks of gestation). We avoid beta-adrenergic receptor agonists as they can cause severe hyperglycemia in patients with diabetes. (See <a class="local">'Preterm birth'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delivery </strong>(See <a class="local">'Delivery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For patients</strong> <strong>with well-controlled hyperglycemia and without vascular complications or macrosomia</strong>, we suggest induction at 39+0 to 39+6 weeks of gestation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), in the absence of standard obstetric or medical indications for earlier intervention or cesarean birth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For patients with uncontrolled hyperglycemia, vascular complications, or history of stillbirth and without macrosomia,</strong> we suggest induction at 36+0 to 38+6 weeks (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), in the absence of standard obstetric or medical indications for earlier intervention or cesarean birth. The timing of birth within this range depends on patient-specific factors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For patients with estimated fetal weight (EFW) &gt;4500 grams</strong>, we suggest planned cesarean rather than vaginal birth (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). The risk of shoulder dystocia is increased at birth weights &gt;4000 grams and high at birth weights &gt;4500 grams  (<a class="graphic graphic_table graphicRef75719" href="/z/d/graphic/75719.html" rel="external">table 5</a>). </p><p></p><p class="bulletIndent2">Since both diabetes and forceps- or vacuum-assisted vaginal birth are associated with an increased risk for shoulder dystocia, it is reasonable to perform a cesarean rather than an assisted vaginal birth in patients with diabetes and EFW &gt;4000 grams.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glycemic management</strong> – Insulin requirements drop sharply after delivery and are transiently lower than requirements prior to pregnancy. (See  <a class="medical medical_review" href="/z/d/html/4441.html" rel="external">"Pregestational (preexisting) and gestational diabetes: Intrapartum and postpartum glucose management", section on 'Postpartum management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Breastfeeding</strong> – Patients with diabetes are encouraged to breastfeed. Insulin and <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> are compatible with breastfeeding. (See <a class="local">'Maternal issues'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postpartum depression</strong> – Clinicians should screen for postpartum depression, which appears to be more common in patients with diabetes. (See <a class="local">'Maternal issues'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraception</strong> – The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=4806" target="_blank">United States Medical Eligibility Criteria for Contraceptive Use</a> consider all hormonal methods acceptable for patients with diabetes and <strong>no vascular disease</strong>, but depot medroxyprogesterone may raise glucose levels so close self-monitoring is required.</p><p></p><p class="bulletIndent2">In patients <strong>with vascular disease</strong>, combined hormonal contraceptives and depot medroxyprogesterone are avoided. (See <a class="local">'Maternal issues'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surveillance for retinopathy</strong> – Eye examinations are continued for one year postpartum, as indicated by the degree of retinopathy. (See <a class="local">'Dilated, comprehensive eye examination'</a> above.)</p><p></p><p class="headingAnchor" id="H597220354"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael F Greene, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sacks DA, Metzger BE. Classification of diabetes in pregnancy: time to reassess the alphabet. Obstet Gynecol 2013; 121:345.</a></li><li><a class="nounderline abstract_t">White P. Classification of obstetric diabetes. Am J Obstet Gynecol 1978; 130:228.</a></li><li><a class="nounderline abstract_t">Diamond MP, Salyer SL, Vaughn WK, et al. Reassessment of White's classification and Pedersen's prognostically bad signs of diabetic pregnancies in insulin-dependent diabetic pregnancies. Am J Obstet Gynecol 1987; 156:599.</a></li><li><a class="nounderline abstract_t">Bennett SN, Tita A, Owen J, et al. Assessing White's classification of pregestational diabetes in a contemporary diabetic population. Obstet Gynecol 2015; 125:1217.</a></li><li><a class="nounderline abstract_t">Cormier CM, Martinez CA, Refuerzo JS, et al. White's classification of diabetes in pregnancy in the 21st century: is it still valid? Am J Perinatol 2010; 27:349.</a></li><li><a class="nounderline abstract_t">Relph S, Patel T, Delaney L, et al. Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis. PLoS Med 2021; 18:e1003856.</a></li><li><a class="nounderline abstract_t">Xie W, Dai P, Qin Y, et al. Effectiveness of telemedicine for pregnant women with gestational diabetes mellitus: an updated meta-analysis of 32 randomized controlled trials with trial sequential analysis. BMC Pregnancy Childbirth 2020; 20:198.</a></li><li><a class="nounderline abstract_t">Ringholm L, Pedersen-Bjergaard U, Thorsteinsson B, et al. Hypoglycaemia during pregnancy in women with Type 1 diabetes. Diabet Med 2012; 29:558.</a></li><li><a class="nounderline abstract_t">García-Patterson A, Gich I, Amini SB, et al. Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. Diabetologia 2010; 53:446.</a></li><li><a class="nounderline abstract_t">Powe CE, Huston Presley LP, Locascio JJ, Catalano PM. Augmented insulin secretory response in early pregnancy. Diabetologia 2019; 62:1445.</a></li><li><a class="nounderline abstract_t">Edelson PK, James KE, Leong A, et al. Longitudinal Changes in the Relationship Between Hemoglobin A1c and Glucose Tolerance Across Pregnancy and Postpartum. J Clin Endocrinol Metab 2020; 105:e1999.</a></li><li><a class="nounderline abstract_t">Finneran MM, Kiefer MK, Ware CA, et al. The use of longitudinal hemoglobin A1c values to predict adverse obstetric and neonatal outcomes in pregnancies complicated by pregestational diabetes. Am J Obstet Gynecol MFM 2020; 2:100069.</a></li><li><a class="nounderline abstract_t">Cahill AG, Tuuli MG, Colvin R, et al. Markers of Glycemic Control and Neonatal Morbidity in High-Risk Insulin-Resistant Pregnancies. Am J Perinatol 2016; 33:151.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S282.</a></li><li><a class="nounderline abstract_t">Tita AT, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med 2022; 386:1781.</a></li><li class="breakAll">Clinical Guidance for the Integration of the Findingsof the Chronic Hypertension and Pregnancy (CHAP) Study. Practice Advisory. 2022. Available at: https://www.acog.org/ (Accessed on April 14, 2022).</li><li><a class="nounderline abstract_t">Campbell KH, Savitz D, Werner EF, et al. Maternal morbidity and risk of death at delivery hospitalization. Obstet Gynecol 2013; 122:627.</a></li><li><a class="nounderline abstract_t">Rosenberg TJ, Garbers S, Lipkind H, Chiasson MA. Maternal obesity and diabetes as risk factors for adverse pregnancy outcomes: differences among 4 racial/ethnic groups. Am J Public Health 2005; 95:1545.</a></li><li><a class="nounderline abstract_t">Ray JG, Vermeulen MJ, Shapiro JL, Kenshole AB. Maternal and neonatal outcomes in pregestational and gestational diabetes mellitus, and the influence of maternal obesity and weight gain: the DEPOSIT study. Diabetes Endocrine Pregnancy Outcome Study in Toronto. QJM 2001; 94:347.</a></li><li><a class="nounderline abstract_t">Bo S, Menato G, Signorile A, et al. Obesity or diabetes: what is worse for the mother and for the baby? Diabetes Metab 2003; 29:175.</a></li><li><a class="nounderline abstract_t">Siegel AM, Tita A, Biggio JR, Harper LM. Evaluating gestational weight gain recommendations in pregestational diabetes. Am J Obstet Gynecol 2015; 213:563.e1.</a></li><li><a class="nounderline abstract_t">Scifres CM, Feghali MN, Althouse AD, et al. Effect of excess gestational weight gain on pregnancy outcomes in women with type 1 diabetes. Obstet Gynecol 2014; 123:1295.</a></li><li><a class="nounderline abstract_t">Egan AM, Dennedy MC, Al-Ramli W, et al. ATLANTIC-DIP: excessive gestational weight gain and pregnancy outcomes in women with gestational or pregestational diabetes mellitus. J Clin Endocrinol Metab 2014; 99:212.</a></li><li><a class="nounderline abstract_t">Yee LM, Cheng YW, Inturrisi M, Caughey AB. Effect of gestational weight gain on perinatal outcomes in women with type 2 diabetes mellitus using the 2009 Institute of Medicine guidelines. Am J Obstet Gynecol 2011; 205:257.e1.</a></li><li><a class="nounderline abstract_t">Parellada CB, Asbjörnsdóttir B, Ringholm L, et al. Fetal growth in relation to gestational weight gain in women with type 2 diabetes: an observational study. Diabet Med 2014; 31:1681.</a></li><li><a class="nounderline abstract_t">Bartsch E, Medcalf KE, Park AL, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ 2016; 353:i1753.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 326:1186.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol 2018; 132:e228. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018; 218:287.</a></li><li><a class="nounderline abstract_t">Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017; 377:613.</a></li><li><a class="nounderline abstract_t">Macintosh MC, Fleming KM, Bailey JA, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ 2006; 333:177.</a></li><li><a class="nounderline abstract_t">Greene MF, Hare JW, Cloherty JP, et al. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology 1989; 39:225.</a></li><li><a class="nounderline abstract_t">Miller E, Hare JW, Cloherty JP, et al. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med 1981; 304:1331.</a></li><li><a class="nounderline abstract_t">Ylinen K, Aula P, Stenman UH, et al. Risk of minor and major fetal malformations in diabetics with high haemoglobin A1c values in early pregnancy. Br Med J (Clin Res Ed) 1984; 289:345.</a></li><li><a class="nounderline abstract_t">Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care 2007; 30:1920.</a></li><li><a class="nounderline abstract_t">Holmes VA, Young IS, Patterson CC, et al. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care 2011; 34:1683.</a></li><li><a class="nounderline abstract_t">Sibai BM, Caritis S, Hauth J, et al. Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 2000; 182:364.</a></li><li><a class="nounderline abstract_t">Savvidou MD, Geerts L, Nicolaides KH. Impaired vascular reactivity in pregnant women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol 2002; 186:84.</a></li><li><a class="nounderline abstract_t">Milunsky A, Alpert E, Kitzmiller JL, et al. Prenatal diagnosis of neural tube defects. VIII. The importance of serum alpha-fetoprotein screening in diabetic pregnant women. Am J Obstet Gynecol 1982; 142:1030.</a></li><li><a class="nounderline abstract_t">Ray JG, Vermeulen MJ, Meier C, Wyatt PR. Risk of congenital anomalies detected during antenatal serum screening in women with pregestational diabetes. QJM 2004; 97:651.</a></li><li><a class="nounderline abstract_t">Evans MI, Harrison HH, O'Brien JE, et al. Correction for insulin-dependent diabetes in maternal serum alpha-fetoprotein testing has outlived its usefulness. Am J Obstet Gynecol 2002; 187:1084.</a></li><li><a class="nounderline abstract_t">Langer O. Ultrasound biometry evolves in the management of diabetes in pregnancy. Ultrasound Obstet Gynecol 2005; 26:585.</a></li><li><a class="nounderline abstract_t">Starikov R, Bohrer J, Goh W, et al. Hemoglobin A1c in pregestational diabetic gravidas and the risk of congenital heart disease in the fetus. Pediatr Cardiol 2013; 34:1716.</a></li><li><a class="nounderline abstract_t">Odibo AO, Coassolo KM, Stamilio DM, et al. Should all pregnant diabetic women undergo a fetal echocardiography? A cost-effectiveness analysis comparing four screening strategies. Prenat Diagn 2006; 26:39.</a></li><li><a class="nounderline abstract_t">Sekhavat S, Kishore N, Levine JC. Screening fetal echocardiography in diabetic mothers with normal findings on detailed anatomic survey. Ultrasound Obstet Gynecol 2010; 35:178.</a></li><li><a class="nounderline abstract_t">Jaeggi ET, Fouron JC, Proulx F. Fetal cardiac performance in uncomplicated and well-controlled maternal type I diabetes. Ultrasound Obstet Gynecol 2001; 17:311.</a></li><li><a class="nounderline abstract_t">Martin RB, Duryea EL, Mcintire DD, et al. Fetal Anomaly Detection in Pregnancies With Pregestational Diabetes. J Ultrasound Med 2020; 39:1917.</a></li><li><a class="nounderline abstract_t">Sibai BM, Caritis SN, Hauth JC, et al. Preterm delivery in women with pregestational diabetes mellitus or chronic hypertension relative to women with uncomplicated pregnancies. The National institute of Child health and Human Development Maternal- Fetal Medicine Units Network. Am J Obstet Gynecol 2000; 183:1520.</a></li><li><a class="nounderline abstract_t">Greene MF, Hare JW, Krache M, et al. Prematurity among insulin-requiring diabetic gravid women. Am J Obstet Gynecol 1989; 161:106.</a></li><li><a class="nounderline abstract_t">Mimouni F, Miodovnik M, Siddiqi TA, et al. High spontaneous premature labor rate in insulin-dependent diabetic pregnant women: an association with poor glycemic control and urogenital infection. Obstet Gynecol 1988; 72:175.</a></li><li><a class="nounderline abstract_t">Reece EA, Sivan E, Francis G, Homko CJ. Pregnancy outcomes among women with and without diabetic microvascular disease (White's classes B to FR) versus non-diabetic controls. Am J Perinatol 1998; 15:549.</a></li><li><a class="nounderline abstract_t">Fisher JE, Smith RS, Lagrandeur R, Lorenz RP. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol 1997; 90:880.</a></li><li><a class="nounderline abstract_t">Bedalov A, Balasubramanyam A. Glucocorticoid-induced ketoacidosis in gestational diabetes: sequela of the acute treatment of preterm labor. A case report. Diabetes Care 1997; 20:922.</a></li><li><a class="nounderline abstract_t">Mathiesen ER, Christensen AB, Hellmuth E, et al. Insulin dose during glucocorticoid treatment for fetal lung maturation in diabetic pregnancy: test of an algorithm [correction of analgoritm]. Acta Obstet Gynecol Scand 2002; 81:835.</a></li><li><a class="nounderline abstract_t">Refuerzo JS, Garg A, Rech B, et al. Continuous glucose monitoring in diabetic women following antenatal corticosteroid therapy: a pilot study. Am J Perinatol 2012; 29:335.</a></li><li><a class="nounderline abstract_t">Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med 2016; 374:1311.</a></li><li class="breakAll">Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery http://www.ajog.org/article/S0002-9378(16)00475-0/pdf (Accessed on November 16, 2016).</li><li><a class="nounderline abstract_t">Starikov R, Dudley D, Reddy UM. Stillbirth in the pregnancy complicated by diabetes. Curr Diab Rep 2015; 15:11.</a></li><li><a class="nounderline abstract_t">Philipps AF, Porte PJ, Stabinsky S, et al. Effects of chronic fetal hyperglycemia upon oxygen consumption in the ovine uterus and conceptus. J Clin Invest 1984; 74:279.</a></li><li><a class="nounderline abstract_t">Cohn HE, Cohen WR, Piasecki GJ, Jackson BT. The effect of hyperglycemia on acid-base and sympathoadrenal responses in the hypoxemic fetal monkey. J Dev Physiol 1992; 17:299.</a></li><li><a class="nounderline abstract_t">Shelley HJ, Bassett JM, Milner RD. Control of carbohydrate metabolism in the fetus and newborn. Br Med Bull 1975; 31:37.</a></li><li><a class="nounderline abstract_t">Robillard JE, Sessions C, Kennedy RL, Smith FG Jr. Metabolic effects of constant hypertonic glucose infusion in well-oxygenated fetuses. Am J Obstet Gynecol 1978; 130:199.</a></li><li><a class="nounderline abstract_t">Hay WW Jr, DiGiacomo JE, Meznarich HK, et al. Effects of glucose and insulin on fetal glucose oxidation and oxygen consumption. Am J Physiol 1989; 256:E704.</a></li><li><a class="nounderline abstract_t">Nylund L, Lunell NO, Lewander R, et al. Uteroplacental blood flow in diabetic pregnancy: measurements with indium 113m and a computer-linked gamma camera. Am J Obstet Gynecol 1982; 144:298.</a></li><li><a class="nounderline abstract_t">Indications for Outpatient Antenatal Fetal Surveillance: ACOG Committee Opinion, Number 828. Obstet Gynecol 2021; 137:e177.</a></li><li><a class="nounderline abstract_t">Siddiqui F, James D. Fetal monitoring in type 1 diabetic pregnancies. Early Hum Dev 2003; 72:1.</a></li><li><a class="nounderline abstract_t">Landon MB, Vickers S. Fetal surveillance in pregnancy complicated by diabetes mellitus: is it necessary? J Matern Fetal Neonatal Med 2002; 12:413.</a></li><li><a class="nounderline abstract_t">Jørgensen IL, Vestgaard M, Ásbjörnsdóttir B, et al. Routine use of antenatal nonstress tests in pregnant women with diabetes-What is the practice? Eur J Obstet Gynecol Reprod Biol 2020; 248:89.</a></li><li><a class="nounderline abstract_t">Signore C, Freeman RK, Spong CY. Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop. Obstet Gynecol 2009; 113:687.</a></li><li><a class="nounderline abstract_t">Lampl M, Jeanty P. Exposure to maternal diabetes is associated with altered fetal growth patterns: A hypothesis regarding metabolic allocation to growth under hyperglycemic-hypoxemic conditions. Am J Hum Biol 2004; 16:237.</a></li><li><a class="nounderline abstract_t">Klemetti MM, Laivuori H, Tikkanen M, et al. White's classification and pregnancy outcome in women with type 1 diabetes: a population-based cohort study. Diabetologia 2016; 59:92.</a></li><li><a class="nounderline abstract_t">Maresh MJ, Holmes VA, Patterson CC, et al. Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. Diabetes Care 2015; 38:34.</a></li><li><a class="nounderline abstract_t">Ehrenberg HM, Mercer BM, Catalano PM. The influence of obesity and diabetes on the prevalence of macrosomia. Am J Obstet Gynecol 2004; 191:964.</a></li><li><a class="nounderline abstract_t">Cyganek K, Skupien J, Katra B, et al. Risk of macrosomia remains glucose-dependent in a cohort of women with pregestational type 1 diabetes and good glycemic control. Endocrine 2017; 55:447.</a></li><li><a class="nounderline abstract_t">Benedetti TJ, Gabbe SG. Shoulder dystocia. A complication of fetal macrosomia and prolonged second stage of labor with midpelvic delivery. Obstet Gynecol 1978; 52:526.</a></li><li><a class="nounderline abstract_t">McElwee ER, Oliver EA, McFarling K, et al. Risk of Stillbirth in Pregnancies Complicated by Diabetes, Stratified by Fetal Growth. Obstet Gynecol 2023; 141:801.</a></li><li class="breakAll">Acker DB, Barss VA. Obstetrical complications. In: Diabetes Complication Pregnancy, 2nd ed, Brown FM, Hare JW (Eds) (Eds), Wiley-Liss, New York 1995. p.153.</li><li><a class="nounderline abstract_t">Modanlou HD, Komatsu G, Dorchester W, et al. Large-for-gestational-age neonates: anthropometric reasons for shoulder dystocia. Obstet Gynecol 1982; 60:417.</a></li><li><a class="nounderline abstract_t">Langer O, Berkus MD, Huff RW, Samueloff A. Shoulder dystocia: should the fetus weighing greater than or equal to 4000 grams be delivered by cesarean section? Am J Obstet Gynecol 1991; 165:831.</a></li><li><a class="nounderline abstract_t">Ecker JL, Greenberg JA, Norwitz ER, et al. Birth weight as a predictor of brachial plexus injury. Obstet Gynecol 1997; 89:643.</a></li><li><a class="nounderline abstract_t">Dildy GA, Clark SL. Shoulder dystocia: risk identification. Clin Obstet Gynecol 2000; 43:265.</a></li><li><a class="nounderline abstract_t">Neufeld ND, Scott M, Kaplan SA. Ontogeny of the mammalian insulin receptor. Studies of human and rat fetal liver plasma membranes. Dev Biol 1980; 78:151.</a></li><li><a class="nounderline abstract_t">Greco P, Vimercati A, Scioscia M, et al. Timing of fetal growth acceleration in women with insulin-dependent diabetes. Fetal Diagn Ther 2003; 18:437.</a></li><li><a class="nounderline abstract_t">Ben-Haroush A, Chen R, Hadar E, et al. Accuracy of a single fetal weight estimation at 29-34 weeks in diabetic pregnancies: can it predict large-for-gestational-age infants at term? Am J Obstet Gynecol 2007; 197:497.e1.</a></li><li><a class="nounderline abstract_t">Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol 1996; 87:163.</a></li><li class="breakAll">ACOG Practice Bulletin #22: Fetal Macrosomia. Reaffirmed 2013.</li><li><a class="nounderline abstract_t">Scioscia M, Vimercati A, Ceci O, et al. Estimation of birth weight by two-dimensional ultrasonography: a critical appraisal of its accuracy. Obstet Gynecol 2008; 111:57.</a></li><li><a class="nounderline abstract_t">Combs CA, Rosenn B, Miodovnik M, Siddiqi TA. Sonographic EFW and macrosomia: is there an optimum formula to predict diabetic fetal macrosomia? J Matern Fetal Med 2000; 9:55.</a></li><li><a class="nounderline abstract_t">Dashe JS, Nathan L, McIntire DD, Leveno KJ. Correlation between amniotic fluid glucose concentration and amniotic fluid volume in pregnancy complicated by diabetes. Am J Obstet Gynecol 2000; 182:901.</a></li><li><a class="nounderline abstract_t">Biggio JR Jr, Wenstrom KD, Dubard MB, Cliver SP. Hydramnios prediction of adverse perinatal outcome. Obstet Gynecol 1999; 94:773.</a></li><li><a class="nounderline abstract_t">Consortium on Safe Labor, Hibbard JU, Wilkins I, et al. Respiratory morbidity in late preterm births. JAMA 2010; 304:419.</a></li><li><a class="nounderline abstract_t">Tita AT, Landon MB, Spong CY, et al. Timing of elective repeat cesarean delivery at term and neonatal outcomes. N Engl J Med 2009; 360:111.</a></li><li><a class="nounderline abstract_t">Robert MF, Neff RK, Hubbell JP, et al. Association between maternal diabetes and the respiratory-distress syndrome in the newborn. N Engl J Med 1976; 294:357.</a></li><li><a class="nounderline abstract_t">Piper JM, Xenakis EM, Langer O. Delayed appearance of pulmonary maturation markers is associated with poor glucose control in diabetic pregnancies. J Matern Fetal Med 1998; 7:148.</a></li><li><a class="nounderline abstract_t">Torday J, Carson L, Lawson EE. Saturated phosphatidylcholine in amniotic fluid and prediction of the respiratory-distress syndrome. N Engl J Med 1979; 301:1013.</a></li><li><a class="nounderline abstract_t">Boulvain M, Senat MV, Perrotin F, et al. Induction of labour versus expectant management for large-for-date fetuses: a randomised controlled trial. Lancet 2015; 385:2600.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion, Number 831. Obstet Gynecol 2021; 138:e35.</a></li><li><a class="nounderline abstract_t">Patient Safety and Quality Committee, Society for Maternal-Fetal Medicine. Electronic address: <span class="__cf_email__" data-cfemail="d9aab4bfb499aab4bfb4f7b6abbe">[email protected]</span>, Hameed AB, Combs CA. Society for Maternal-Fetal Medicine Special Statement: Updated checklist for antepartum care of pregestational diabetes mellitus. Am J Obstet Gynecol 2020; 223:B2.</a></li><li><a class="nounderline abstract_t">McCall JO. Shoulder dystocia: A study of after effects. Am J Obstet Gynecol 1962; 83:1486.</a></li><li><a class="nounderline abstract_t">Acker DB, Sachs BP, Friedman EA. Risk factors for shoulder dystocia. Obstet Gynecol 1985; 66:762.</a></li><li><a class="nounderline abstract_t">Golditch IM, Kirkman K. The large fetus. Management and outcome. Obstet Gynecol 1978; 52:26.</a></li><li><a class="nounderline abstract_t">Rouse DJ, Owen J, Goldenberg RL, Cliver SP. The effectiveness and costs of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound. JAMA 1996; 276:1480.</a></li><li><a class="nounderline abstract_t">Wladimiroff JW, Bloemsma CA, Wallenburg HC. Ultrasonic diagnosis of the large-for-dates infant. Obstet Gynecol 1978; 52:285.</a></li><li><a class="nounderline abstract_t">Macrosomia: ACOG Practice Bulletin, Number 216. Obstet Gynecol 2020; 135:e18. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Practice Bulletins-Gynecology, The American College of Obstetrician and Gynecologists. ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists. Number 40, November 2002. Obstet Gynecol 2002; 100:1045.</a></li><li><a class="nounderline abstract_t">Nesbitt TS, Gilbert WM, Herrchen B. Shoulder dystocia and associated risk factors with macrosomic infants born in California. Am J Obstet Gynecol 1998; 179:476.</a></li><li><a class="nounderline abstract_t">Cormier CM, Landon MB, Lai Y, et al. White's classification of maternal diabetes and vaginal birth after cesarean delivery success in women undergoing a trial of labor. Obstet Gynecol 2010; 115:60.</a></li><li><a class="nounderline abstract_t">Gabbe SG, Mestman JH, Freeman RK, et al. Management and outcome of pregnancy in diabetes mellitus, classes B to R. Am J Obstet Gynecol 1977; 129:723.</a></li><li><a class="nounderline abstract_t">Olofsson P, Ingemarsson I, Solum T. Fetal distress during labour in diabetic pregnancy. Br J Obstet Gynaecol 1986; 93:1067.</a></li><li><a class="nounderline abstract_t">Achong N, Duncan EL, McIntyre HD, Callaway L. Peripartum management of glycemia in women with type 1 diabetes. Diabetes Care 2014; 37:364.</a></li><li><a class="nounderline abstract_t">Nørgaard SK, Nørgaard K, Roskjær AB, et al. Insulin Pump Settings During Breastfeeding in Women with Type 1 Diabetes. Diabetes Technol Ther 2020; 22:314.</a></li><li><a class="nounderline abstract_t">Kozhimannil KB, Pereira MA, Harlow BL. Association between diabetes and perinatal depression among low-income mothers. JAMA 2009; 301:842.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2014; :CD006133.</a></li><li><a class="nounderline abstract_t">Visser J, Snel M, Van Vliet HA. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2. Cochrane Database Syst Rev 2013; :CD003990.</a></li><li><a class="nounderline abstract_t">Kim C, Seidel KW, Begier EA, Kwok YS. Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 2001; 161:1766.</a></li><li><a class="nounderline abstract_t">Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res 2000; 26:17.</a></li><li><a class="nounderline abstract_t">O'Brien SH, Koch T, Vesely SK, Schwarz EB. Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes. Diabetes Care 2017; 40:233.</a></li></ol></div><div id="topicVersionRevision">Topic 4806 Version 80.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23344285" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Classification of diabetes in pregnancy: time to reassess the alphabet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/619663" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Classification of obstetric diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3826207" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Reassessment of White's classification and Pedersen's prognostically bad signs of diabetic pregnancies in insulin-dependent diabetic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25932851" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Assessing White's classification of pregestational diabetes in a contemporary diabetic population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20013582" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : White's classification of diabetes in pregnancy in the 21st century: is it still valid?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34807920" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32252676" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effectiveness of telemedicine for pregnant women with gestational diabetes mellitus: an updated meta-analysis of 32 randomized controlled trials with trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22313112" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hypoglycaemia during pregnancy in women with Type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20013109" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31177313" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Augmented insulin secretory response in early pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32010954" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Longitudinal Changes in the Relationship Between Hemoglobin A1c and Glucose Tolerance Across Pregnancy and Postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33345983" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The use of longitudinal hemoglobin A1c values to predict adverse obstetric and neonatal outcomes in pregnancies complicated by pregestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26332585" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Markers of Glycemic Control and Neonatal Morbidity in High-Risk Insulin-Resistant Pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078583" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35363951" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment for Mild Chronic Hypertension during Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35363951" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment for Mild Chronic Hypertension during Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23921870" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Maternal morbidity and risk of death at delivery hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16118366" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Maternal obesity and diabetes as risk factors for adverse pregnancy outcomes: differences among 4 racial/ethnic groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435630" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Maternal and neonatal outcomes in pregestational and gestational diabetes mellitus, and the influence of maternal obesity and weight gain: the DEPOSIT study. Diabetes Endocrine Pregnancy Outcome Study in Toronto.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746640" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Obesity or diabetes: what is worse for the mother and for the baby?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26220111" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evaluating gestational weight gain recommendations in pregestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24807331" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of excess gestational weight gain on pregnancy outcomes in women with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24187402" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : ATLANTIC-DIP: excessive gestational weight gain and pregnancy outcomes in women with gestational or pregestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071055" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of gestational weight gain on perinatal outcomes in women with type 2 diabetes mellitus using the 2009 Institute of Medicine guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25081349" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fetal growth in relation to gestational weight gain in women with type 2 diabetes: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27094586" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34581729" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30461693" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29138036" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657417" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16782722" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2727930" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7012627" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6432090" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk of minor and major fetal malformations in diabetics with high haemoglobin A1c values in early pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446531" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21636798" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10694338" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11810090" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Impaired vascular reactivity in pregnant women with insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6176126" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prenatal diagnosis of neural tube defects. VIII. The importance of serum alpha-fetoprotein screening in diabetic pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367735" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk of congenital anomalies detected during antenatal serum screening in women with pregestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12389009" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Correction for insulin-dependent diabetes in maternal serum alpha-fetoprotein testing has outlived its usefulness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254874" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ultrasound biometry evolves in the management of diabetes in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23619831" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hemoglobin A1c in pregestational diabetic gravidas and the risk of congenital heart disease in the fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16378332" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Should all pregnant diabetic women undergo a fetal echocardiography? A cost-effectiveness analysis comparing four screening strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20101639" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Screening fetal echocardiography in diabetic mothers with normal findings on detailed anatomic survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11339187" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Fetal cardiac performance in uncomplicated and well-controlled maternal type I diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32323894" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fetal Anomaly Detection in Pregnancies With Pregestational Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120521" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Preterm delivery in women with pregestational diabetes mellitus or chronic hypertension relative to women with uncomplicated pregnancies. The National institute of Child health and Human Development Maternal- Fetal Medicine Units Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2665491" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prematurity among insulin-requiring diabetic gravid women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3393360" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : High spontaneous premature labor rate in insulin-dependent diabetic pregnant women: an association with poor glycemic control and urogenital infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9890254" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pregnancy outcomes among women with and without diabetic microvascular disease (White's classes B to FR) versus non-diabetic controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9397094" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9167100" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Glucocorticoid-induced ketoacidosis in gestational diabetes: sequela of the acute treatment of preterm labor. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12225298" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Insulin dose during glucocorticoid treatment for fetal lung maturation in diabetic pregnancy: test of an algorithm [correction of analgoritm].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22094918" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Continuous glucose monitoring in diabetic women following antenatal corticosteroid therapy: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26842679" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Antenatal Betamethasone for Women at Risk for Late Preterm Delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26842679" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antenatal Betamethasone for Women at Risk for Late Preterm Delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25667005" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Stillbirth in the pregnancy complicated by diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6429196" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effects of chronic fetal hyperglycemia upon oxygen consumption in the ovine uterus and conceptus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1289392" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The effect of hyperglycemia on acid-base and sympathoadrenal responses in the hypoxemic fetal monkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1180997" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Control of carbohydrate metabolism in the fetus and newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23007" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Metabolic effects of constant hypertonic glucose infusion in well-oxygenated fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2660584" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of glucose and insulin on fetal glucose oxidation and oxygen consumption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7124844" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Uteroplacental blood flow in diabetic pregnancy: measurements with indium 113m and a computer-linked gamma camera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34011892" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Indications for Outpatient Antenatal Fetal Surveillance: ACOG Committee Opinion, Number 828.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12706307" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fetal monitoring in type 1 diabetic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12683653" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fetal surveillance in pregnancy complicated by diabetes mellitus: is it necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32199298" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Routine use of antenatal nonstress tests in pregnant women with diabetes-What is the practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300336" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15101051" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Exposure to maternal diabetes is associated with altered fetal growth patterns: A hypothesis regarding metabolic allocation to growth under hyperglycemic-hypoxemic conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26474777" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : White's classification and pregnancy outcome in women with type 1 diabetes: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25368104" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15467573" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The influence of obesity and diabetes on the prevalence of macrosomia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27726091" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Risk of macrosomia remains glucose-dependent in a cohort of women with pregestational type 1 diabetes and good glycemic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/724169" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Shoulder dystocia. A complication of fetal macrosomia and prolonged second stage of labor with midpelvic delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36897128" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Risk of Stillbirth in Pregnancies Complicated by Diabetes, Stratified by Fetal Growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36897128" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Risk of Stillbirth in Pregnancies Complicated by Diabetes, Stratified by Fetal Growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7121926" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Large-for-gestational-age neonates: anthropometric reasons for shoulder dystocia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951539" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Shoulder dystocia: should the fetus weighing greater than or equal to 4000 grams be delivered by cesarean section?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166293" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Birth weight as a predictor of brachial plexus injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10863625" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Shoulder dystocia: risk identification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6995214" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Ontogeny of the mammalian insulin receptor. Studies of human and rat fetal liver plasma membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14564116" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Timing of fetal growth acceleration in women with insulin-dependent diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17980186" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Accuracy of a single fetal weight estimation at 29-34 weeks in diabetic pregnancies: can it predict large-for-gestational-age infants at term?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559516" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A United States national reference for fetal growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559516" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A United States national reference for fetal growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18165393" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Estimation of birth weight by two-dimensional ultrasonography: a critical appraisal of its accuracy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10757437" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Sonographic EFW and macrosomia: is there an optimum formula to predict diabetic fetal macrosomia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764470" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Correlation between amniotic fluid glucose concentration and amniotic fluid volume in pregnancy complicated by diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10546727" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hydramnios prediction of adverse perinatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664042" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Respiratory morbidity in late preterm births.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129525" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Timing of elective repeat cesarean delivery at term and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1246288" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Association between maternal diabetes and the respiratory-distress syndrome in the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9642613" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Delayed appearance of pulmonary maturation markers is associated with poor glucose control in diabetic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/492233" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Saturated phosphatidylcholine in amniotic fluid and prediction of the respiratory-distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25863654" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Induction of labour versus expectant management for large-for-date fetuses: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34259491" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion, Number 831.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32861689" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Society for Maternal-Fetal Medicine Special Statement: Updated checklist for antepartum care of pregestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Shoulder dystocia: A study of after effects</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4069477" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk factors for shoulder dystocia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/683626" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The large fetus. Management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8903259" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The effectiveness and costs of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/703983" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Ultrasonic diagnosis of the large-for-dates infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31856124" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Macrosomia: ACOG Practice Bulletin, Number 216.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12434783" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists. Number 40, November 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731856" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Shoulder dystocia and associated risk factors with macrosomic infants born in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20027035" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : White's classification of maternal diabetes and vaginal birth after cesarean delivery success in women undergoing a trial of labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/607804" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Management and outcome of pregnancy in diabetes mellitus, classes B to R.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3790466" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Fetal distress during labour in diabetic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24130361" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Peripartum management of glycemia in women with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31580150" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Insulin Pump Settings During Breastfeeding in Women with Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19244191" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Association between diabetes and perinatal depression among low-income mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24788670" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543528" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11485510" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Diabetes and depot medroxyprogesterone contraception in Navajo women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10761326" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27899496" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
